BNT-162b1 is under clinical development by BioNTech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Acasunlimab is under clinical development by BioNTech and currently in Phase III for Non-Small Cell Lung Cancer.

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Medical Accompaniment Service market is estimated to be valued at USD 45.2 Mn in 2024 and is expected to reach USD 74.5 Mn by 2031, exhibiting a CAGR of 7.4%. Mr. Shah Coherent Market Insights Pvt.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Biontech SE agreed to pay up to nearly $1.26 billion in two separate settlements to resolve royalty disputes with the U.S. NIH and the University of Pennsylvania related to the COVID-19 vaccine the ...